Treatment for prevention of HIV transmission in a localised epidemic: the case for South Australia
Kelly-Jean Heymer A and David P. Wilson A B
+ Author Affiliations
- Author Affiliations
A National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Darlinghurst, Sydney, NSW 2010, Australia.
B Corresponding author. Email: dwilson@nchecr.unsw.edu.au
Sexual Health 8(3) 280-294 https://doi.org/10.1071/SH10084
Submitted: 8 July 2010 Accepted: 30 November 2010 Published: 23 May 2011
Abstract
Background: Discussion is currently taking place among international HIV/AIDS groups around increasing HIV testing and initiating earlier use of antiretroviral therapy (ART) among people diagnosed with HIV as a method to reduce the spread of HIV. In this study, we explore the expected epidemiological impact of this strategy in a small population in which HIV transmission is predominantly confined to men who have sex with men (MSM). Methods: A deterministic mathematical transmission model was constructed to investigate the impacts of strategies that increase testing and treatment rates, and their likely potential to mitigate HIV epidemics among MSM. Our novel model distinguishes men in the population who are more easily accessible to prevention campaigns through engagement with the gay community from men who are not. This model is applied to the population of MSM in South Australia. Results: Our model-based findings suggest that increasing testing rates alone will have minimal impact on reducing the expected number of infections compared to current conditions. However, in combination with increases in treatment coverage, this strategy could lead to a 59–68% reduction in the number of HIV infections over the next 5 years. Targeting men who are socially engaged with the gay community would result in the majority of potential reductions in incidence, with only minor improvements possible by reaching all other MSM. Conclusions: Investing in strategies that will achieve higher coverage and earlier initiation of treatment to reduce infectiousness of HIV-infected individuals could be an effective strategy for reducing incidence in a population of MSM.
Additional keywords: HIV, mathematical model, men who have sex with men, test and treat, South Australia.
References
[1] Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373 48–57.| Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model.Crossref | GoogleScholarGoogle Scholar |
[2] Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000; 342 921–9.
| Viral load and heterosexual transmission of human immunodeficiency virus type 1.Crossref | GoogleScholarGoogle Scholar |
[3] Vernazza PL, Gilliam BL, Dyer J, Fiscus SA, Eron JJ, Frank AC, et al Quantification of HIV in semen: correlation with antiviral treatment and immune status. AIDS 1997; 11 987–93.
| Quantification of HIV in semen: correlation with antiviral treatment and immune status.Crossref | GoogleScholarGoogle Scholar |
[4] Vernazza PL, Troiani L, Flepp MJ, Cone RW, Schock J, Roth F, et al Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. AIDS 2000; 14 117–21.
| Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study.Crossref | GoogleScholarGoogle Scholar |
[5] Zhang H, Dornadula G, Beumont M, Livornese L. Zhang H, Dornadula G, Beumont M, Livornese L. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med 1998; 339 1803–9.
| Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy.Crossref | GoogleScholarGoogle Scholar |
[6] Porco TC, Martin JN, Page-Shafer KA, Cheng A, Charlebois E, Grant RM, et al Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS 2004; 18 81–8.
| Decline in HIV infectivity following the introduction of highly active antiretroviral therapy.Crossref | GoogleScholarGoogle Scholar |
[7] Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, Cohen CR, et al Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010; 375 2092–8.
| Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis.Crossref | GoogleScholarGoogle Scholar |
[8] Attia S, Egger M, Müller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009; 23 1397–404.
| Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis.Crossref | GoogleScholarGoogle Scholar |
[9] Wilson DP. Universal voluntary HIV testing and immediate antiretroviral therapy. Lancet 2009; 373 1077–8, author reply 1080–1.
| Universal voluntary HIV testing and immediate antiretroviral therapy.Crossref | GoogleScholarGoogle Scholar |
[10] Dieffenbach CW, Fauci AS. Universal voluntary testing and treatment for prevention of HIV transmission. JAMA 2009; 301 2380–2.
| Universal voluntary testing and treatment for prevention of HIV transmission.Crossref | GoogleScholarGoogle Scholar |
[11] Wagner BG, Kahn JS, Blower S. Should we try to eliminate HIV epidemics by using a ‘test and treat’ strategy? AIDS 2010; 24 775–6.
| Should we try to eliminate HIV epidemics by using a ‘test and treat’ strategy?Crossref | GoogleScholarGoogle Scholar |
[12] Wilson DP. Evidence is still required for treatment as prevention for riskier routes of HIV transmission. AIDS 2010; 24 2891–2.
| Evidence is still required for treatment as prevention for riskier routes of HIV transmission.Crossref | GoogleScholarGoogle Scholar |
[13] Das M, Lee Chu P, Santos G-M, Scheer S, Vittinghoff E, McFarland W, et al Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One 2010; 5 e11068
| Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco.Crossref | GoogleScholarGoogle Scholar |
[14] van Griensven F, de Lind van Wijngaarden JW, Baral S, Grulich A. The global epidemic of HIV infection among men who have sex with men. Curr Opin HIV AIDS 2009; 4 300–7.
| The global epidemic of HIV infection among men who have sex with men.Crossref | GoogleScholarGoogle Scholar |
[15] Grulich AE, Kaldor JM. Trends in HIV incidence in homosexual men in developed countries. Sex Health 2008; 5 113–8.
| Trends in HIV incidence in homosexual men in developed countries.Crossref | GoogleScholarGoogle Scholar |
[16] Sullivan PS, Hamouda O, Delpech V, Geduld JE, Prejean J, Semaille C, et al Reemergence of the HIV epidemic among men who have sex with men in North America, Western Europe, and Australia, 1996–2005. Ann Epidemiol 2009; 19 423–31.
| Reemergence of the HIV epidemic among men who have sex with men in North America, Western Europe, and Australia, 1996–2005.Crossref | GoogleScholarGoogle Scholar |
[17] Jin F, Jansson J, Law M, Prestage GP, Zablotska I, Imrie JCG, et al Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART. AIDS 2010; 24 907–13.
| Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART.Crossref | GoogleScholarGoogle Scholar |
[18] Lima VD, Hogg RS, Montaner JS. Expanding HAART treatment to all currently eligible individuals under the 2008 IAS-USA Guidelines in British Columbia, Canada. PLoS One 2010; 5 e10991
| Expanding HAART treatment to all currently eligible individuals under the 2008 IAS-USA Guidelines in British Columbia, Canada.Crossref | GoogleScholarGoogle Scholar |
[19] National Centre in HIV Epidemiology and Clinical Research. In: McDonald A, editor. HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia. Annual surveillance report. Sydney: National Centre in HIV Epidemiology and Clinical Research, University of New South Wales; 2009.
[20] Wilson DP, Hoare A, Regan D, Wand H, Law M. Mathematical models to investigate recent trends in HIV notifications among men who have sex with men in Australia. Sydney: National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales; 2008.
[21] Prestage G, Ferris J, Grierson J, Thorpe R, Zablotska I, Imrie J, et al Homosexual men in Australia: population, distribution and HIV prevalence. Sex Health 2008; 5 97–102.
| Homosexual men in Australia: population, distribution and HIV prevalence.Crossref | GoogleScholarGoogle Scholar |
[22] Rawstorne P, Holt M, Kippax S, Worth H, Wilkinson J, Bittman M. E-Male survey 2008: key findings from a national online survey of men who have sex with men. Sydney: National Centre in HIV Social Research; 2009.
[23] Frankland A, Zablotska I, Prestage G, O’Connor S, Martin P, Imrie J. Adelaide gay community periodic survey. Sydney: National Centre in HIV Social Research, University of New South Wales; 2007.
[24] Kippax S, Connell R, Dowsett GW, Crawford J. Sustaining safe sex: gay communities respond to AIDS. London: Routledge; 1993.
[25] Wilson DP, Hoare A, Regan DG, Law MG. Importance of promoting HIV testing for preventing secondary transmissions: modelling the Australian HIV epidemic among men who have sex with men. Sex Health 2009; 6 19–33.
| Importance of promoting HIV testing for preventing secondary transmissions: modelling the Australian HIV epidemic among men who have sex with men.Crossref | GoogleScholarGoogle Scholar |
[26] Prestage G, Hudson J, Bradley J, Down I, Sutherland R, Corrigan N, et al. TOMS: three or more study. Sydney: National Centre in HIV Epidemiology and Clinical Research, University of New South Wales; 2008.
[27] Lima VD, Johnston K, Hogg RS, Levy AR, Harrigan PR, Anema A, et al Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis 2008; 198 59–67.
| Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic.Crossref | GoogleScholarGoogle Scholar |
[28] Velasco-Hernandez JX, Gershengorn HB, Blower SM. Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? Lancet Infect Dis 2002; 2 487–93.
| Could widespread use of combination antiretroviral therapy eradicate HIV epidemics?Crossref | GoogleScholarGoogle Scholar |
[29] Baggaley RF, Garnett GP, Ferguson NM. Modelling the impact of antiretroviral use in resource-poor settings. PLoS Med 2006; 3 e124
| Modelling the impact of antiretroviral use in resource-poor settings.Crossref | GoogleScholarGoogle Scholar |
[30] Salomon JA, Hogan DR. Evaluating the impact of antiretroviral therapy on HIV transmission. AIDS 2008; 22 S149–59.
| Evaluating the impact of antiretroviral therapy on HIV transmission.Crossref | GoogleScholarGoogle Scholar |
[31] Johnston KM, Levy AR, Lima VD, Hogg RS, Tyndall MW, Gustafson P, et al Expanding access to HAART: a cost-effective approach for treating and preventing HIV. AIDS 2010; 24 1929–35.
| Expanding access to HAART: a cost-effective approach for treating and preventing HIV.Crossref | GoogleScholarGoogle Scholar |
[32] Jin F, Crawford J, Prestage GP, Zablotska I, Imrie J, Kippax SC, et al Unprotected anal intercourse, risk reduction behaviours, and subsequent HIV infection in a cohort of homosexual men. AIDS 2009; 23 243–52.
| Unprotected anal intercourse, risk reduction behaviours, and subsequent HIV infection in a cohort of homosexual men.Crossref | GoogleScholarGoogle Scholar |
[33] Prestage G, McCann PD, Hurley M, Bradley J, Down I, Brown G. Pleasure and sexual health: The PASH Study, 2009. Sydney: National Centre in HIV Epidemiology and Clinical Research; 2010.
[34] Kinloch-de Loës S, Hirschel BJ, Hoen B, Cooper DA, Tindall B, Carr A, et al A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995; 333 408–13.
| A controlled trial of zidovudine in primary human immunodeficiency virus infection.Crossref | GoogleScholarGoogle Scholar |
[35] Hammer SM, Saag MS, Schechter M, Montaner JSG, Schooley RT, Jacobsen DM, et al Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society – USA panel. JAMA 2006; 296 827–43.
| Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society – USA panel.Crossref | GoogleScholarGoogle Scholar |
[36] Rawstorne P, Holt M, Kippax S, Worth H, Wilkinson J, Bittman M. Supplemental data analysis to the E-Male survey: data comparisons of the E-Male survey in South Australia and the Adelaide Gay Community Periodic Survey. Sydney: NCHSR, University of New South Wales; 2009.
[37] Davis KR, Weller SC. The effectiveness of condoms in reducing heterosexual transmission of HIV. Fam Plann Perspect 1999; 31 272–9.
| The effectiveness of condoms in reducing heterosexual transmission of HIV.Crossref | GoogleScholarGoogle Scholar |
[38] Weller SC, Davis KR. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2002; CD003255
| Condom effectiveness in reducing heterosexual HIV transmission.Crossref | GoogleScholarGoogle Scholar |
[39] Pinkerton SD, Abtramson PR. Effectiveness of condoms in preventing HIV transmission. Soc Sci Med 1997; 44 1303–12.
| Effectiveness of condoms in preventing HIV transmission.Crossref | GoogleScholarGoogle Scholar |
[40] Weller SC. A meta-analysis of condom effectiveness in reducing sexually transmitted HIV. Soc Sci Med 1993; 36 1635–44.
| A meta-analysis of condom effectiveness in reducing sexually transmitted HIV.Crossref | GoogleScholarGoogle Scholar |
[41] Fitch TJ, Stine C, Hager WD, Mann J, Adam MB, McIlhaney J. Condom effectiveness: factors that influence risk reduction. Sex Transm Dis 2002; 29 811–7.
| Condom effectiveness: factors that influence risk reduction.Crossref | GoogleScholarGoogle Scholar |
[42] Van de Ven P, Mao L, Fogarty A, Rawstorne P, Crawford J, Prestage G, et al Undetectable viral load is associated with sexual risk taking in HIV serodiscordant gay couples in Sydney. AIDS 2005; 19 179–84.
| Undetectable viral load is associated with sexual risk taking in HIV serodiscordant gay couples in Sydney.Crossref | GoogleScholarGoogle Scholar |
[43] National Centre in HIV Social Research. National Centre in HIV Social Research annual report of trends in behaviour. Sydney: NCHSR, University of New South Wales; 2006.
[44] Marks G, Crepaz N, Senterfitt JW, Janssen RS. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr 2005; 39 446–53.
| Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs.Crossref | GoogleScholarGoogle Scholar |
[45] Cleary PD, Van Devanter N, Rogers TF, Singer E, Shipton-Levy R, Steilen M, et al Behavior changes after notification of HIV infection. Am J Public Health 1991; 81 1586–90.
| Behavior changes after notification of HIV infection.Crossref | GoogleScholarGoogle Scholar |
[46] Colfax GN, Buchbinder SP, Cornelisse PGA, Vittinghoff E, Mayer K, Celum C. Sexual risk behaviors and implications for secondary HIV transmission during and after HIV seroconversion. AIDS 2002; 16 1529–35.
| Sexual risk behaviors and implications for secondary HIV transmission during and after HIV seroconversion.Crossref | GoogleScholarGoogle Scholar |
[47] McCusker J, Stoddard AM, Mayer KH, Zapka J, Morrison C, Saltzman SP. Effects of HIV antibody test knowledge on subsequent sexual behaviors in a cohort of homosexually active men. Am J Public Health 1988; 78 462–7.
| Effects of HIV antibody test knowledge on subsequent sexual behaviors in a cohort of homosexually active men.Crossref | GoogleScholarGoogle Scholar |
[48] Saah AJ, Hoover DR, Weng S, Carrington M, Mellors J, Rinaldo CR. Saah AJ, Hoover DR, Weng S, Carrington M, Mellors J, Rinaldo CR. Association of HLA profiles with early plasma viral load, CD4+ cell count and rate of progression to AIDS following acute HIV-1 infection. Multicenter AIDS Cohort Study. AIDS 1998; 12 2107–13.
| Association of HLA profiles with early plasma viral load, CD4+ cell count and rate of progression to AIDS following acute HIV-1 infection. Multicenter AIDS Cohort Study.Crossref | GoogleScholarGoogle Scholar |
[49] Smith DK, Valleroy LA, Warren DL, Vlahov D, Schuman P, Stein MD, et al Design and baseline participant characteristics of the Human Immunodeficiency Virus Epidemiology Research (HER) study: a prospective cohort study of human immunodeficiency virus infection in US women. Am J Epidemiol 1997; 146 459–69.
[50] Valleroy LA, MacKellar DA, Karon JM, Rosen DH, McFarland W, Shehan DA, et al HIV prevalence and associated risks in young men who have sex with men. Young Men’s Survey Study Group. JAMA 2000; 284 198–204.
| HIV prevalence and associated risks in young men who have sex with men. Young Men’s Survey Study Group.Crossref | GoogleScholarGoogle Scholar |
[51] Law MG, Prestage G, Grulich A, Van de Ven P, Kippax S. Modelling the effect of combination antiretroviral treatments on HIV incidence. AIDS 2001; 15 1287–94.
| Modelling the effect of combination antiretroviral treatments on HIV incidence.Crossref | GoogleScholarGoogle Scholar |
[52] Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126 946–54.
[53] Worm SW, Friis-Møller N, Sabin CA, Sjøl A, Lundgren JD, Salbøl-Brandt R, et al Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010; 24 1537–48.
[54] Ledergerber B, and The PLATO Collaboration. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004; 364 51–62.
| Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes.Crossref | GoogleScholarGoogle Scholar |
[55] Jin F, Jansson J, Law M, Prestage GP, Zablotska I, Imrie JCG, et al Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART. AIDS 2010; 24 907–13.
| Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART.Crossref | GoogleScholarGoogle Scholar |
[56] Wilson DP, Law MG, Grulich AE, Cooper DA, Kaldor JM. Relation between HIV viral load and infectiousness: a model-based analysis. Lancet 2008; 372 314–20.
| Relation between HIV viral load and infectiousness: a model-based analysis.Crossref | GoogleScholarGoogle Scholar |
[57] Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342 921–9.
| Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group.Crossref | GoogleScholarGoogle Scholar |
[58] Australian HIV Observational Database Annual Report. Sydney: National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales; 2009.
[59] Lodwick RK, Smith CJ, Youle M, Lampe FC, Tyrer M, Bhagani S, et al Stability of antiretroviral regimens in patients with viral suppression. AIDS 2008; 22 1039–46.
| Stability of antiretroviral regimens in patients with viral suppression.Crossref | GoogleScholarGoogle Scholar |
